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Background: Chronic kidney disease (CKD) is common and disproportionally burdens
United States ethnic minorities. Its genetic determinants may differ by disease severity
and clinical stages. To uncover genetic factors associated CKD severity among high-
risk ethnic groups, we performed genome-wide association studies (GWAS) in diverse
populations within the Population Architecture using Genomics and Epidemiology
(PAGE) study.
Methods: We assembled multi-ethnic genome-wide imputed data on CKD non-
overlapping cases [4,150 mild to moderate CKD, 1,105 end-stage kidney disease
(ESKD)] and non-CKD controls for up to 41,041 PAGE participants (African
Americans, Hispanics/Latinos, East Asian, Native Hawaiian, and American Indians). We
implemented a generalized estimating equation approach for GWAS using ancestry
combined data while adjusting for age, sex, principal components, study, and ethnicity.
Results: The GWAS identified a novel genome-wide associated locus for mild to
moderate CKD nearby NMT2 (rs10906850, p = 3.7 × 10−8) that replicated in the
United Kingdom Biobank white British (p = 0.008). Several variants at the APOL1 locus
were associated with ESKD including the APOL1 G1 rs73885319 (p = 1.2 × 10−9).
There was no overlap among associated loci for CKD and ESKD traits, even at
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the previously reported APOL1 locus (p = 0.76 for CKD). Several additional loci were
associated with CKD or ESKD at p-values below the genome-wide threshold. These
loci were often driven by variants more common in non-European ancestry.
Conclusion: Our genetic study identified a novel association at NMT2 for CKD and
showed for the first time strong associations of the APOL1 variants with ESKD across
multi-ethnic populations. Our findings suggest differences in genetic effects across
CKD severity and provide information for study design of genetic studies of CKD in
diverse populations.
Keywords: genetics, chronic kidney disease stages, genome-wide association studies, APOL1, end stage kidney
disease, diverse populations, single nucleotide polymorphisms
INTRODUCTION
Chronic kidney disease (CKD) affects 15% of United States.
adults and is a leading cause of death globally (Global Burden
of Disease 2016 Causes of Death Collaborators, 2017). CKD
is classified based on its causes, kidney function (estimated
glomerular filtration rate, eGFR), and markers of kidney damage
(Levin and Stevens, 2014). The risk of adverse outcomes and
disability greatly increases in advanced CKD (Go et al., 2004;
Saran et al., 2018). There is a high burden of CKD in non-
European ancestry groups, including African Americans and
Hispanics/Latinos (Collins et al., 2011). Genetic susceptibility
explains in part ethnic differences in the burden of CKD,
as illustrated by the African-ancestry APOL1 G1 and G2
genotypes that contribute to increased CKD risk in individuals
with African ancestry (Genovese et al., 2010; Kramer et al.,
2017). Approximately 13% of African Americans carry two
APOL1 risk genotypes G1 (composed of two missense variants),
G2 (a 6-base pair in-frame deletion) or are compound
heterozygous of G1 and G2 genotypes. APOL1 encodes an HDL
cholesterol-binding protein but mechanisms related to CKD
risk are unknown.
Few genome-wide association studies (GWAS) have been
published for CKD as the primary outcome. These include
studies of CKD progression such as the Chronic Renal
Insufficiency Cohort Study (Parsa et al., 2017), and cause-
specific CKD such as GWAS consortia that compared individuals
with diabetic nephropathy with non-CKD diabetes controls
(Iyengar et al., 2015; van Zuydam et al., 2018), in addition to
studies of glomerular diseases (for example, IgA nephropathy,
membranous nephropathy) (GWAS Catalog, 2019). CKD is a
heterogeneous condition and its genetic determinants may vary
by CKD severity, with more advanced CKD possibly reflecting
stronger genetic risk. The genetic determinants of CKD severity
have not been previously studied, particularly among individuals
of diverse ancestries that vary in their genetic susceptibility.
Our recent research in diverse populations within the
Continental Origins and Genetic Epidemiology Network
(COGENT) Kidney Consortium identified 93 novel loci
for eGFR, displaying homogenous effects across four major
ancestries (Morris et al., 2019). Using Mendelian Randomization,
we have shown that identified single nucleotide variants (SNVs)
were causally related to a clinical diagnosis of CKD from
International Classification of Disease (ICD) diagnosis billing
codes in the United Kingdom Biobank. These SNVs, identified
from the trans-ethnic analyses and showing homogenous effects
across ancestries, more likely capture CKD genetic risk across
diverse populations.
To identify novel risk loci associated with CKD severity
(stages), we assembled multi-ethnic data on cases (4,150
mild to moderate CKD and 1,105 ESKD) and non-CKD
controls for samples up to 41,041 participants within the
Population Architecture using Genomics and Epidemiology
(PAGE) study (Bien et al., 2016). We also examined the
association of eGFR-identified GWAS variants with CKD




The PAGE consortium includes eligible minority participants
from four studies. The Women’s Health Initiative (WHI) is a
long-term, prospective, multi-center, and multi-ethnic cohort
study investigating post-menopausal women’s health recruited
from 1993 to 1998 at 40 centers across the United States
(Anderson et al., 2003). WHI participants of European descent
were excluded from analyses. The Hispanic Community Health
Study/Study of Latinos (HCHS/SOL) is a multi-center study
of Hispanic/Latinos with the goal of determining the role of
acculturation in the prevalence and development of diseases
relevant to Hispanic/Latino health. Starting in 2006, household
sampling was used to recruit self-identified Hispanic/Latinos
from four sites in San Diego, CA, Chicago, IL, Bronx,
NY, and Miami, FL (Sorlie et al., 2010). The Multiethnic
Cohort (MEC) is a population-based prospective cohort study
recruiting men and women aged 45–75 from Hawaii and
Los Angeles, California, in 1993–1996, that examines lifestyle
risk factors and genetic susceptibility for cancer across five
racial/ethnic groups (Kolonel et al., 2000). Only the African
American, Japanese American, and Native Hawaiian participants
for MEC were included in analyses. The BioMe BioBank is
an Electronic Medical Record-linked biobank that integrates
research data and clinical care information for consented patients
at the Mount Sinai Medical Center, which serves diverse local
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communities of upper Manhattan with broad health disparities.
Recruitment began in 2007 and continues at 30 clinical care sites
throughout New York City. BioMe participants were African
American, Hispanic/Latino, primarily of Caribbean origin (36%),
Caucasian (30%), and Others who did not identify with any
of the available options (9%) (Nadkarni et al., 2014). All
PAGE participants have provided informed consent. Up to
41,041 participants with kidney phenotype information were
included in analyses.
Genotypes and Imputation
The genotyping and quality control (QC) in PAGE has been
previously described (Bien et al., 2016). Briefly, 53,426 samples
were genotyped centrally at the Center for Inherited Disease
Research (CIDR) in the Johns Hopkins University using
the Multi-Ethnic Genotyping Array (MEGA), Consortium
version, consisting of 1,705,969 single nucleotide variants
(SNV). Genotypes were called using the GenomeStudio version
2001.1, Genotyping Module 1.9.4, and GenTrain version 1.0.
Extensive QC was performed to the combined genotyping data,
which included checks for gender discrepancies, Mendelian
inconsistencies, unexpected duplication, unexpected non-
duplication, poor performance, or DNA mixture. Samples with
identity issues, restricted consent, and duplicates were also
removed (final sample 51,520 subjects). SNVs were filtered if
they had a missing call rate ≥ 2%, more than 6 discordant calls
in 988 study duplicates, > 1 Mendelian errors in 282 trios and
1,439 duos, a Hardy–Weinberg p-value < 10−4, sex difference in
allele frequency ≥ 0.2 and sex difference in heterozygosity >0.3
for autosome chromosomes. After SNV QC, a total of 1,438,399
SNVs were available for analyses.
Imputation was done centrally at the University of
Washington in combined samples. The study samples were
phased with SHAPEIT2 (Delaneau et al., 2013) and imputed with
IMPUTE2 (Howie et al., 2009) to the 1000 Genomes Project
Phase 3 data release. Reference panel variants were restricted
to a minor allele count (MAC) ≥2 across all 1000. Kinship
coefficients were estimated using PC-Relate (Conomos et al.,
2016). Principal components (PCs) were estimated in unrelated
individuals within the global study population using SNVRelate
package (Zheng et al., 2012). The first 10 PCs explained most of
the genetic variation in the PAGE study population.
CKD Phenotypes
For studies with available serum creatinine (HCHS/SOL, WHI),
we calculated eGFR using the CKD-EPI equation and baseline
cohort data (Inker et al., 2012). Mild to moderate CKD
(referred as CKD) was defined by an eGFR between 15 and
60 ml/min/1.73 m2 (HCHS/SOL, WHI) or by an ICD-9 or
10 code in medical claims (585.1-585.5, 585.9, N18.1-N18.5,
N18.9) (MEC, BioMe) (Nadkarni et al., 2014). Advanced CKD
(referred as ESKD) was defined by an eGFR < 15 ml/min/1.73 m2
(HCHS/SOL), an ICD-9 or 10 code of 585.6 or N18.6 related
to ESKD (MEC) or ESKD obtained through linkage to the
United States Renal Data System (BioMe). CKD and ESKD
cases were mutually exclusive. Controls were individuals with an
eGFR > 60 ml/min/1.73 m2 or without ICD codes related to
CKD or ESKD. In sensitivity analyses, we used two additional
definitions for mild to moderate CKD: one based on ICD codes
(MEC and BioMe data) and one based on eGFR from cohort
studies (HCHS/SOL, WHI).
Statistical Analyses
We performed genome-wide association analyses of the
combined data using the software SUGEN, which implements
a generalized estimating equation approach and empirically
estimates within-family correlations without modeling the
correlation structures of complex pedigrees (Lin et al., 2014).
SUGEN adopts a modified version of the sandwich variance
estimator, which replaces the empirical covariance matrix of the
score vectors by the Fisher information matrix for unrelated
subjects. We used logistic regression to analyze categorical
phenotypes, and included age, sex, ten PCs, study, center (if
available), and ethnicity as covariates. We filtered variants with
an effective number <50 based on minor allele frequency of
cases (MAF), number of participants (N) and imputation score
from impute2 (info) using the following calculation [2∗MAF∗(1-
MAF)∗N∗info] where N = total sample for a given phenotype.
P-values were generated by score tests. Significant threshold
for GWAS was p < 5.0 × 10−8 and suggestive threshold was a
p < 1.0 × 10−7.
For SNVs with p < 10−7, we used the clumping procedure
INDEP in Easystrata to identify independent signals at each locus
which included on 1 Mb genomic interval flanking the lead
SNVs. We also examined if the published loci for eGFR were
associated with CKD or ESKD. We prioritized eGFR variants
identified in the multi-ethnic COGENT-Kidney consortium and
also used variants available in the Genome catalog for CKD and
ESKD. For the APOL1 locus, we performed analysis conditioning
on the most significant SNV in the region. In sensitivity
analysis, we assessed the significance of SNVs identified in the
GWAS for CKD using CKD definition based on ICD codes or
eGFR thresholds.
Associations in the United Kingdom
Biobank
We assessed the association of our identified variants in the
United Kingdom Biobank for SNVs available in European
ancestry listed in Tables 2, 3. We extracted p-values from
United Kingdom Biobank using GeneATLAS (2019) for ICD-
10 diagnosis codes N18 (chronic renal failure, 4,905 cases,
and 447,359 controls), N19 (unspecified renal failure including
uremia, kidney failure, azotemia, 1,516 cases and 450,748
controls) and renal/kidney failure (759 cases and 451,505
controls) (Gene ATLAS). Publicly available replication samples
for CKD/ESKD in non-European ancestry were not available.
RESULTS
Participant Characteristics
Overall, 41,041 individuals contributed data for CKD analyses
(10.1% cases) and 31,694 individuals to ESKD analyses (3.4%
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TABLE 1 | Descriptive characteristics of mild to moderate CKD and advance CKD stages.
Characteristics CKD Control ESKD Control
(mild to moderate)
Total number 4,150 41,041 1,105 31,694
Mean age (SD), years 63.1 (9.5) 52.5 (13.1) 57.9 (11.4) 50.6 (13.8)
Female, % 61.2 68.2 45.9 59.4
Diabetes, % 53.3 24.7 56.1 24.1
Hypertension, % 92.5 49.6 98.7 48.0
African American, N (%) 1, 532 (37) 13, 761 (34) 584 (53) 8, 429 (27)
Hispanic/Latino, N (%) 1, 336 (32) 19, 317 (47) 282 (26) 15, 852 (50)
East Asian, N (%) 575 (14) 3, 540 (9 112 (10) 3, 536 (11)
Native Hawaiian, N (%) 608 (15) 2, 892 (7) 96 (9) 2, 892 (9)
American Indian, N (%) 42 (1) 595 (2) 1 (0) 49 (0)
Other ethnicity, N (%) 57 (1) 936 (2) 30 (3) 936 (3)
SD, standard deviation; N, number.
TABLE 2 | Main findings for association with mild to moderate CKD at p < 10−7.
Chr:position
(hg19)













Multi-ethnic AFR AMR EUR
1:226523031 rs76064236 G/T 0.005 NA 0.001 0.002 2.28 1.69, 3.16 9.5 × 10−7 PARP1 intergenic
3:128388015 rs146639727 C/G 0.004 0.013 NA NA 3.05 2.04, 4.56 5.1 × 10−8 RPN1 intergenic
8:131963415 rs138873021 T/TAAG 0.629 0.260 0.752 0.818 1.17 1.11, 1.25 1.6 × 10−7 ADCY8 intron
9:12141349 rs186208070 A/T 0.009 0.020 0.003 0.001 2.07 1.59, 2.70 6.7 × 10−8 TYRP1 intergenic
10:15225054 rs10906850 C/T 0.225 0.109 0.242 0.325 1.18 1.11, 1.25 3.7 × 10−8 NMT2 intergenic
11:125840145 rs183951714 T/C 0.011 0.000 0.000 0.000 1.66 1.36, 2.02 7.0 × 10−7 CDON intron
12:105784903 rs117329947 C/A 0.014 0.001 0.027 0.027 1.79 1.42, 2.25 9.3 × 10−7 C12orf75 intergenic
16:63000290 rs11645800 G/A 0.184 0.404 0.085 0.109 1.20 1.12, 1.28 1.4 × 10−7 CDH8 intergenic
16:86761390 rs147084429 T/C 0.019 0.050 0.001 NA 0.63 0.53, 0.76 4.5 × 10−7 FOXL1 intergenic
17:48825516 rs144210385 A/G 0.006 0.001 0.009 0.021 2.85 1.94, 4.17 7.6 × 10−8 LUC7L3 intron
21:41667378 rs2837554 G/A 0.701 NA 0.001 0.002 1.16 1.10, 1.24 3.1 × 10−7 DSCAM intron
21:43048485 rs187652497 C/T 0.007 0.017 0.001 NA 2.23 1.66, 3.00 1.1 × 10−7 LINC00111 intergenic
Chr, chromosome; SE, standard error; SNV, single nucleotide variant; NA, not available; AFR, African; EUR, European; AMR, Ad Mixed American. Models adjusted for
age, sex, study, race/ethnicity and PCs.
cases) with non-overlapping cases. Cases were older and had a
lower proportion of women compared to controls, and more
comorbidities (Table 1). The study-specific contribution for cases
and controls is shown in Supplementary Table 1.
Multi-Ethnic GWAS Findings
The main findings from the GWAS of CKD and ESKD in
combined multi-ethnic samples are shown in Tables 2, 3.
Manhattan plots are shown in Figure 1 and quantile-quantile
(QQ) are shown in Supplementary Figure 1. The genomic
control lambdas were 1.025 for CKD and 1.026 for ESKD.
These analyses identified two genome-wide associated loci: a
chromosome 10 locus nearby NMT2 associated with CKD
(rs10906850, allele frequency 0.23, p = 3.7 × 10−8) (Table 2 and
Figure 2A) and the chromosome 22 APOL1 locus associated with
ESKD (four common SNVs, including the two highly correlated
APOL1 G1 missense variants rs73885319 and rs60910145)
(Figure 2B and Supplementary Table 2). APOL1 G2 indel
was not available in our data. Conditional analysis on the
most significant SNV supported an independent association at
the APOL1 locus.
Several loci with low frequency SNVs had suggestive
evidence for association including SNVs located nearby RPN1
(p = 5.1 × 10−8), TYRP1 (p = 6.7 × 10−8), and LUC7L3
(p = 7.6 × 10−8) associated with CKD, and MIR4790
(p = 8.6 × 10−8) associated with ESKD. Except for LUC7L3,
the most significant SNV at these loci was rare or not present
in European ancestry. For example, the TYRP1 variant allele
frequency in 1000 Genomes Project is 0.02 in African ancestry
and 0.001 in European ancestry, and RPN1 and MIR4790 SNVs
are not available in 1000 Genomes Project European ancestry
samples. Additional SNVs associated with ESKD at p < 10−7
included a low frequency intronic variant in FTO (rs7189997,
p = 2.8 −10−7) and a common variant nearby IRX3 (rs8050506,
p = 9.94 × 10−7). Both SNVs were also more common in African
ancestry reference panels (Table 3).
Nine of the SNVs with significant or suggestive association
with CKD or ESKD (listed in Tables 2, 3) were available
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TABLE 3 | Main association findings with ESKD at p < 10−7.
Chr:position
(hg19)











Multi-ethnic AFR AMR EUR
1:78634021 rs77138376 A/G 0.009 NA NA NA 2.63 1.83, 3,78 1.9 × 10−7 GIPC2 intergenic
1: 146810798 rs12032578 C/T 0.088 0.160 0.033 0.007 1.44 1.25, 1.66 3.1 × 10−7 LINC00624 intergenic
3: 5547449 rs112407915 A/T 0.020 0.047 0.003 NA 1.96 1.53, 2.51 8.6 × 10−8 MIR4790 intergenic
4: 118841271 rs114425659 A/G 0.039 0.023 0.063 0.080 1.87 1.45, 2.39 9.1 × 10−7 NDST3 intergenic
7:11617925 rs74614630 C/T 0.012 0.030 0.003 NA 2.25 1.63, 3.11 9.2 × 10−7 THSD7A intron
9: 79608946 rs115747230 C/T 0.021 0.061 0.004 0.001 1.88 1.47, 2.39 3.6 × 10−7 FOXB2 intergenic
11:24231483 rs116510623 G/A 0.034 0.107 0.009 0.001 1.65 1.35,2.01 6.4 × 10−7 LUZP2 intergenic
13:32883196 rs60236946 T/C 0.021 0.071 0.006 NA 1.86 1.45, 2.38 9.2 × 10−7 ZAR1L intron
14:56825071 rs115007604 A/G 0.008 0.023 0.006 NA 2.67 1.81, 3.95 8.7 × 10−7 PELI2 intergenic
16: 53886224 rs7189997 G/A 0.009 0.027 0.003 NA 2.44 1.73, 3.42 2.8 × 10−7 FTO intron
16: 54413730 rs8050506 A/G 0.211 0.324 0.108 0.119 1.29 1.17, 1.43 7.5 × 10−7 IRX3 5’-UTR
17:14189909 rs191540116 A/G 0.011 0.026 0.01 0.000 2.32 1.66, 3.25 8.6 × 10−7 HS3ST3B1 intergenic
18: 54764414 rs12963285 C/T 0.166 0.269 0.170 0.038 0.74 0.66, 0.84 9.7 × 10−7 LINC-ROR 5’-UTR
22:29461285 rs138572244 A/G 0.008 0.022 0.001 NA 2.90 1.94, 4.35 2.4 × 10−7 C22orf31 intergenic
22: 36661906 rs73885319 G/A 0.077 0.260 0.009 NA 1.51 1.32, 1.72 1.9 × 10−9 APOL1 missense
Chr, chromosome; SE, standard error; SNV, single nucleotide polymorphism; NA, not available; AFR, African; EUR, European; AMR, Ad Mixed American. Models adjusted
for age, sex, study, race/ethnicity and PCs.
for replication in the United Kingdom Biobank white British
samples. The SNV rs10906850 nearby NMT2 was significantly
associated with ICD code for renal/kidney failure (p = 0.008)
and rs11645800 nearby CDH8 was nominally associated with
renal/kidney failure (Table 4). The common indel rs138873021
was not available in the United Kingdom Biobank.
Cross-Association of Significant SNVs
for CKD and ESKD and Sensitivity
Analyses
At the NMT2 locus associated for CKD, the most significant
SNV was not associated with ESKD (p = 0.82). At the
APOL1 locus associated with ESKD, rs73885319 (and other
variants) were not associated with CKD (p = 0.76). To
explore heterogeneity in the definition for CKD that could
explain our findings, we examined the association of the
genome-wide associated significant SNVs in samples stratified
by CKD definition based on ICD code (n = 4,698 cases,
n = 18,764 controls) or eGFR thresholds (n = 3,179 cases,
n = 18,550 controls). The NMT2 SNV rs10906850 was
associated with CKD using both definitions (p = 2.4 × 10−6
for ICD codes and p = 8.2 × 10−3 for eGFR thresholds)
and there was consistency in direction of effects. Conversely,
APOL1 rs73885319 was not associated with CKD using either
definition (p > 0.05).
Association of Previously Reported
eGFR SNVs From the COGENT-Kidney
Consortium With CKD Stages in PAGE
Given PAGE studies included diverse (non-European)
participants, we selected 93 eGFR SNVs identified in the
trans-ethnic COGENT-Kidney Consortium to assess their
association with CKD and ESKD in PAGE. Seventeen loci were
associated with CKD and six loci were associated with ESKD at
nominal p-values (p < 0.05). These SNVs had concordant effect
estimates between the COGENT-Kidney eGFR lowering allele
that showed increased odds of CKD or ESKD (Supplementary
Table 3). The PDILT/UMOD was the only locus that was
associated with both CKD and ESKD.
DISCUSSION
The main finding of this study is the identification of a
new locus for mild to moderate CKD nearby NMT2 for a
SNV common across ancestries. The study also shows for the
first time genome-wide associations of the APOL1 SNVs with
ESKD across multi-ethnic populations. Several other leading
low frequency variants showed suggestive association with CKD
traits. Most of the low frequency associated SNVs were more
common in reference datasets of African ancestry and rare
or absent in individuals of European ancestry, particularly
for findings related to ESKD. These findings were driven by
our discovery samples, which is composed of a large number
of non-European ancestry including African Americans (34%)
and Hispanics/Latinos (46%). Only nine SNVs were available
in the United Kingdom Biobank for a sample of European
ancestry. We replicated the association at the NMT2 locus,
which also showed consistent direction of effects for alleles
between PAGE and the United Kingdom Biobank samples. Of
the remaining eight SNVs brought for replication, four had
consistent direction of effect between CKD discovery and the
United Kingdom Biobank ICD code N18 replication, and one
showed consistent direction of effect between ESKD discovery
and United Kingdom Biobank ICD code N19 and renal/kidney
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FIGURE 1 | Manhattan plots for trans-ethnic GWAS of CKD (A) and ESKD (B). Significant novel (red) and known (blue) loci are highlighted.
Frontiers in Genetics | www.frontiersin.org 6 May 2019 | Volume 10 | Article 494
fgene-10-00494 May 24, 2019 Time: 14:35 # 7
Lin et al. Genetics and Chronic Kidney Disease Stages
FIGURE 2 | Regional plots of the association at the NMT2 (A) with CKD, and the APOL1 locus associated with ESKD (B). Linkage disequilibrium was estimated
from the PAGE multi-ethnic data.
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p OR p OR p OR OR
CKD SNVs
rs10906850 C 0.37 0.16 1.03 0.83 1.01 0.0089 1.15 1.18
rs117329947 C 0.03 0.75 1.02 0.60 0.95 0.34 1.02 1.79
rs11645800 G 0.35 0.63 1.01 0.33 1.04 0.028 1.13 1.20
rs144210385 A 0.02 0.94 1.01 0.31 0.86 0.69 0.92 2.85
rs2837554 G 0.08 0.57 1.02 0.79 0.98 0.12 0.86 1.16
ESKD SNVs
rs12032578 C 0.003 0.96 1.01 0.17 0.61 0.34 0.62 1.44
rs114425659 A 0.05 0.32 0.96 0.87 0.99 0.12 0.83 1.87
rs8050506 A 0.11 0.35 1.03 0.84 1.01 0.64 0.96 1.29
rs12963285 C 0.04 0.34 0.95 0.02 0.80 0.35 0.88 0.74
Indels rs61555057 and rs138873021 are not available in the United Kingdom Biobank. SNV, single nucleotide variant; OR, odds ratio for association of coded allele.
∗ ICD-10 codes in the United Kingdom Biobank.
failure replication, although p-values were not significant. We
were unable to replicate other variants due to their low frequency
or unavailability in samples of European ancestry, and lack of
comparable publicly available summary results for CKD traits in
non-European populations.
Single nucleotide variant rs10906850 is an intergenic variant
located nearby NMT2, a gene that encodes a protein involved
in regulating the function and localization of signaling proteins.
The SNV is an expression quantitative trait (eQTL) for
NMT2 in tibial artery (p = 4.7 × 10−9), adipose tissue
(p = 5.7 × 10−8) and skin (p = 1.6 × 10−7). This locus has
not been previously associated with kidney traits. Additional
locus identified at p < 10−7 for CKD includes ADCY8,
which has been previously described in the CRIC study for
association with eGFR decline among non-diabetic African
Americans, although not at genome-wide significant level
(Parsa et al., 2017). Our SNV in the region (rs138873021)
is in linkage disequilibrium with the SNV identified in the
CRIC study (rs4492355, p = 1.3 × 10−7 in the CRIC study,
D’ = 0.90, r2 = 0.01 in 1000 Genomes Project African
ancestry), although rs4492355 is not associated with CKD in
the study (p = 0.53). Two loci associated with ESKD have been
previously associated with obesity traits (FTO and IRX3), but
our SNVs are low frequency and more common in African
ancestry. Our findings related to the association of eGFR SNVs
identified in the COGENT-Kidney consortium with CKD stages
supports heterogeneity in genetic effects across CKD stages.
We found a larger number of COGENT-Kidney eGFR lowering
SNVs associated with increased CKD than eGFR lowering
SNVs associated with increased ESKD. Only one locus was
associated with both CKD and ESKD in PAGE: rs77924615 at
the PDILT/UMOD locus, which showed nominal associations
with these traits.
Chronic kidney disease is a heterogeneous disease in its
etiology and clinical manifestation, with varying rates of
progression to advanced stages. There is still little understanding
on the mechanisms related to these varying patterns of disease
severity even within the same disease etiology, for example,
diabetic nephropathy. An interesting finding of our study is
that there may be differences in genetic susceptibility based
on the severity of the disease manifestation. We found little
overlap of the most significant loci associated with the CKD
phenotype (that includes mild to moderate CKD stages) and
ESKD (which reflects advanced CKD). For example, the known
APOL1 G1 genotype was not associated with CKD. The NMT2
SNV was significantly associated with CKD but not with
ESKD. Although our study lacks information on the APOL1
G2 SNV, we did not identify additional associations at the
chromosome 22 locus in conditional analyses. The APOL1
risk genotypes, including G1, were identified in admixture
mapping for ESKD attributed to hypertension, FSGS or HIV
(Genovese et al., 2010), and associations have been replicated in
population studies although not at the genome-wide significant
level (Foster et al., 2013; Kramer et al., 2017). Our study
provides evidence for APOL1 association with ESKD among
diverse populations and for ESKD not selected for a specific
disease etiology.
There are several possible explanations for the different
genetic findings by CKD stages. Advanced CKD (ESKD)
may have a stronger genetic component related to CKD
progression, whereas mild to moderate CKD may capture more
genetic factors related to CKD initiation. Mild to moderate
CKD likely has less genetic influences due to inclusion of
older individuals (aging process) and due to environmental
factors. Alternatively, there is greater heterogeneity in our
definition of mild to moderate CKD, opening the possibility
of misclassified cases among individuals with an eGFR
around the threshold of 60 ml/min/1.73 m2. However,
our sensitivity analyses in CKD subgroups defined by ICD
codes or eGFR thresholds did not show differences in the
association for our significant NMT2 locus. Overall, these
findings provide important information for the study design
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of genetic studies for CKD, which should consider phenotype
heterogeneity and severity of disease particularly when CKD
is defined using ICD billing codes and when the definition
includes a mixed case of CKD identified through biomarkers or
clinical disease.
In conclusion, our multi-ethnic study identified a novel
locus for mild to moderate CKD and replicated a known
locus for ESKD. Our results highlight the need for more
studies in diverse populations to identify genetic risk factors
in populations at higher risk for CKD. It also underscores the
current limitations of genetic research in these populations,
including the lack of suitable replication samples for non-
European ancestry variants.
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